TMCnet - World's Largest Communications and Technology Community



Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
[April 01, 2014]

Provectus Biopharmaceuticals' PV-10 Data to Be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting

KNOXVILLE, Tenn. --(Business Wire)--

Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (, a development-stage oncology and dermatology biopharmaceutical company, announced today that data on treatment of cutaneous melanoma using its investigational drug PV-10 have been selected to be part of the Poster Highlights Session of the American Society of Clinical Oncology (ASCO) Annual Meeting this year at McCormick Place, Chicago, IL, May 30-June 3, 2014. The time and date of the session are expected to be available on the ASCO website,, on April 21, 2014.

Sanjiv S. Agarwala, MD, is lead author of abstract #9027, entitled "Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02."

Craig Dees, PhD, CEO of Provetus said, "Being selected for the Poster Highlights Session is an honor, and we look forward to sharing the results of our Phase 2 study with attendees."

Provectus has recently submitted an application to the FDA for breakthrough therapy designation for PV-10 based on the results from its Phase 2 clinical study related to cutaneous melanoma and is researching its efficacy for other indications.

About Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, For additional information about Provectus please visit the Company's website at or contact Porter, LeVay & Rose, Inc.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy